Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

28.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 28.86
Bid (Size) 27.00 (2)
Ask (Size) 29.91 (1)
Prev. Close 28.86
Today's Range 28.86 - 28.86
52wk Range 18.12 - 44.46
Shares Outstanding 49,015,172
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before. 
Via Investor's Business Daily

Performance

YTD
+25.58%
+25.58%
1 Month
+1.76%
+1.76%
3 Month
-20.74%
-20.74%
6 Month
-28.16%
-28.16%
1 Year
+50.70%
+50.70%

More News

Read More
7 Safe Stocks to Rely on When the Market Swerves
Via InvestorPlace
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals's Return on Invested Capital Overview
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
Via ACCESSWIRE
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
Via ACCESSWIRE
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
Via Investor's Business Daily
Amphastar Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
Via Investor's Business Daily
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
Via Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
Via Investor's Business Daily
Amphastar Receives FDA Approval for Vasopressin
Via ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
Via Investor's Business Daily
Prometheus Biosciences Stock Shows Rising Relative Strength
Via Investor's Business Daily
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.